UnitedHealth Group delivered its clearest evidence yet that the turnaround is real, posting second-quarter operating earnings of $8 billion, up from $5.2 billion a year earlier, and raising full-year adjusted earnings guidance to a range of $19.50 to $20 per share. The stock, trading at $421.48, has climbed more than 50 percent over the past twelve months, but the market’s reaction was muted; shares rose just 0.2 percent on the day, suggesting the good news was largely priced in.
The medical cost ratio tells the real story
The most important figure in the report was the medical cost ratio, which improved to 86.7 percent from 89.4 percent a year earlier. That 2.7 percentage-point drop signals the company has regained pricing discipline after the April 2025 shock when Medicare Advantage utilization spiked at roughly twice the rate management had anticipated. Tighter Medicare cost controls and improved Medicaid reimbursement drove the improvement, and the market is finally believing the fix is structural rather than cyclical.
Optum carries its weight
Optum generated $65.7 billion in revenue and $4 billion in earnings, while the UnitedHealthcare insurance arm contributed $86 billion in revenue and $3.9 billion in earnings. Together they produced $112 billion in quarterly revenue. Cash flow from operations reached $11.1 billion, or 1.9 times net income, and the debt-to-capital ratio fell to 41.2 percent from 43.9 percent at year-end 2025, edging toward management’s 40 percent target. The company also repurchased $4 billion of stock through mid-July and is on track for at least $5 billion for the full year.
Analysts are warm but not hot
Twenty-seven analysts rate the stock a Moderate Buy with a $455.92 average price target, roughly 7 percent upside from current levels. That consensus reflects a company that has worked through higher medical costs and portfolio changes but still has to prove the turnaround is durable. The 27.1x P/E multiple and 2.2 percent dividend yield suggest the market is paying for quality in a resilient sector, not for explosive growth. What to watch next is whether the medical cost ratio can hold below 87 percent through the back half of the year without a tailwind from Medicaid reimbursement timing.